Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer

Seminars in Cell and Developmental Biology

Volumn 52, Issue , 2016, Pages 39-46

  Rad, Ellie ^a   Tee, Andrew R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cancer; MPNST; Neurofibromin; NF1; Tumour suppressor

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; FOCAL ADHESION KINASE 1; MICRORNA; NEUROFIBROMIN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN;

CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SIGNALING ASSAY; CYTOSKELETON; HUMAN; LOSS OF FUNCTION MUTATION; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MEMBRANE STRUCTURE; NEUROFIBROMATOSIS TYPE 1; ONCOGENE RAS; REVIEW; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ANIMAL; DISEASE COURSE; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; NEUROFIBROMATOSIS 1; SIGNAL TRANSDUCTION;

EID: 84961207132     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2016.02.007     Document Type: Review

References (65)

1. Crump T. Translation of case reports in Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen by F. v. Recklinghausen. Adv. Neurol. 1981, 29:259-275. http://www.ncbi.nlm.nih.gov/pubmed/6798841 (accessed 20.07.15).
2. Boyd K.P., Korf B.R., Theos A. Neurofibromatosis type 1. J. Am. Acad. Dermatol. 2009, 61:1-14. 10.1016/j.jaad.2008.12.051.
3. Ferner R.E. Neurofibromatosis 1. Eur. J. Hum. Genet. 2007, 15:131-138. 10.1038/sj.ejhg.5201676.
4. Dogra B.B., Rana K.S. Facial plexiform neurofibromatosis: a surgical challenge. Indian Dermatol. Online J. 2013, 4:195--198. 10.4103/2229-5178.115515.
5. Barker D., Wright E., Nguyen K., Cannon L., Fain P., Goldgar D., et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 1987, 236:1100-1102. http://www.ncbi.nlm.nih.gov/pubmed/3107130 (accessed 22.07.15).
6. Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Faryniarz A.G., Chao M.V., et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 1987, 49:589-594. 10.1016/0092-8674(87) 90534-4.
7. Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., Saulino A.M., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181-186. http://www.ncbi.nlm.nih.gov/pubmed/2134734 (accessed 22.07.15).
8. Fain P.R., Goldgar D.E., Wallace M.R., Collins F.S., Wright E., Nguyen K., et al. Refined physical and genetic mapping of the NF1 region on chromosome 17. Am. J. Hum. Genet. 1989, 45:721-728. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1683433&tool=pmcentrez&rendertype=abstract (accessed 22.07.15).
9. Schmidt M.A., Michels V.V., Dewald G.W., Opitz J.M., Reynolds J.F. Cases of neurofibromatosis with rearrangements of chromosome 17 involving band 17q11.2. Am. J. Med. Genet. 1987, 28:771-777. 10.1002/ajmg.1320280333.
10. Collins F.S., O'Connell P., Ponder B.A., Seizinger B.R. Progress towards identifying the neurofibromatosis (NF1) gene. Trends Genet. 1989, 5:217-221. http://www.ncbi.nlm.nih.gov/pubmed/2506682 (accessed 22.07.15).
11. Menon A.G., Ledbetter D.H., Rich D.C., Seizinger B.R., Rouleau G.A., Michels V.F., et al. Characterization of a translocation within the von Recklinghausen neurofibromatosis region of chromosome 17. Genomics 1989, 5:245-249. http://www.ncbi.nlm.nih.gov/pubmed/2507442 (accessed 22.07.15).
12. Cawthon R.M., Weiss R., Xu G.F., Viskochil D., Culver M., Stevens J., et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990, 62:193-201. http://www.ncbi.nlm.nih.gov/pubmed/2114220 (accessed 22.06.15).
13. Viskochil D., Buchberg a M., Xu G., Cawthon R.M., Stevens J., Wolff R.K., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187-192. 10.1016/0092-8674(90)90252-A.
14. Seminog O.O., Goldacre M.J. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br. J. Cancer 2013, 108:193-198. 10.1038/bjc.2012.535.
15. Ratner N., Miller S.J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 2015, 15:290-301. 10.1038/nrc3911.
16. Mitin N., Rossman K.L., Der C.J. Signaling interplay in Ras superfamily function. Curr. Biol. 2005, 15:R563-R574. 10.1016/j.cub.2005.07.010.
17. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22. 10.1038/nrc969.
18. Goodsell D.S. The molecular perspective: the ras oncogene. Oncologist. 1999, 4:263-264. http://theoncologist.alphamedpress.org/content/4/3/263 (accessed 09.06.15).
19. Aramini J.M., Vorobiev S.M., Tuberty L.M., Janjua H., Campbell E.T., Seetharaman J., et al. The RAS-binding domain of human BRAF protein serine/threonine kinase exhibits allosteric conformational changes upon binding HRAS. Structure 2015, 10.1016/j.str.2015.06.003.
20. Lavoie H., Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat. Rev. Mol. Cell Biol. 2015, 16:281-298. 10.1038/nrm3979.
21. Welti S., Kühn S., D'Angelo I., Brügger B., Kaufmann D., Scheffzek K. Structural and biochemical consequences of NF1 associated nontruncating mutations in the Sec14-pH module of neurofibromin. Hum. Mutat. 2011, 32:191-197. 10.1002/humu.21405.
22. Hancock J.F., Parton R.G. Ras plasma membrane signalling platforms. Biochem. J. 2005, 389:1-11. 10.1042/BJ20050231.
23. Ahearn I.M., Haigis K., Bar-Sagi D., Philips M.R. Regulating the regulator: post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 2012, 13:39-51. 10.1038/nrm3255.
24. Mavrakis K.J., Zhu H., Silva R.L.A., Mills J.R., Teruya-Feldstein J., Lowe S.W., et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 2008, 22:2178-2188. 10.1101/gad.1690808.
25. Dodd K.M., Yang J., Shen M.H., Sampson J.R., Tee a R. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 2014, 1-12. 10.1038/onc.2014.164.
26. Ozawa T., Araki N., Yunoue S., Tokuo H., Feng L., Patrakitkomjorn S., et al. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J. Biol. Chem. 2005, 280:39524--39533. 10.1074/jbc.M503707200.
27. Vallée B., Doudeau M., Godin F., Gombault A., Tchalikian A., de Tauzia M., et al. Nf1 RasGAP Inhibition of LIMK2 Mediates a New Cross-Talk between Ras and Rho Pathways. PLoS One 2012, 7:e47283. 10.1371/journal.pone.0047283.
28. Starinsky-Elbaz S., Faigenbloom L., Friedman E., Stein R., Kloog Y. The pre-GAP-related domain of neurofibromin regulates cell migration through the LIM kinase/cofilin pathway. Mol. Cell. Neurosci. 2009, 42:278-287. 10.1016/j.mcn.2009.07.014.
29. Gregory P.E., Gutmann D.H., Mitchell A., Park S., Boguski M., Jacks T., et al. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat. Cell Mol. Genet. 1993, 19:265-274. http://www.ncbi.nlm.nih.gov/pubmed/8332934 (accessed 27.07.15).
30. Kweh F., Zheng M., Kurenova E., Wallace M., Golubovskaya V., Cance W.G. Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase. Mol. Carcinog. 2009, 48:1005-1017. 10.1002/mc.20552.
31. Tsai P.-I., Wang M., Kao H.-H., Cheng Y.-J., Walker J.A., Chen R.-H., et al. Neurofibromin Mediates FAK Signaling in Confining Synapse Growth at Drosophila Neuromuscular Junctions. J. Neurosci. 2012, 32:16971-16981. 10.1523/JNEUROSCI.1756-12.2012.
32. Feng L., Yunoue S., Tokuo H., Ozawa T., Zhang D., Patrakitkomjorn S., et al. PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin. FEBS Lett. 2004, 557:275--282. http://www.ncbi.nlm.nih.gov/pubmed/14741381 (accessed 19.10.15).
33. Patrakitkomjorn S., Kobayashi D., Morikawa T., Wilson M.M., Tsubota N., Irie A., et al. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2. J. Biol. Chem. 2008, 283:9399-9413. 10.1074/jbc.M708206200.
34. Korf B.R. Malignancy in neurofibromatosis type 1. Oncologist 2000, 5:477-485. 10.1634/theoncologist.5-6-477.
35. Zehou O., Fabre E., Zelek L., Sbidian E., Ortonne N., Banu E., et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J. Rare Dis. 2013, 8:127. 10.1186/1750-1172-8-127.
36. Kahn J., Gillespie A., Tsokos M., Ondos J., Dombi E., Camphausen K., et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front. Oncol. 2014, 4:324. 10.3389/fonc.2014.00324.
37. Yang J.C., Chang A.E., Baker A.R., Sindelar W.F., Danforth D.N., Topalian S.L., et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 1998, 16:197-203. http://www.ncbi.nlm.nih.gov/pubmed/9440743 (accessed 31.08.15).
38. Beert E., Brems H., Daniëls B., De Wever I., Van Calenbergh F., Schoenaers J., et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes. Chromosomes Cancer 2011, 50:1021-1032. 10.1002/gcc.20921.
39. Upadhyaya M., Spurlock G., Thomas L., Thomas N.S.T., Richards M., Mautner V.-F., et al. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum. Mutat. 2012, 33:763-776. 10.1002/humu.22044.
40. Tabone-Eglinger S., Bahleda R., Côté J.-F., Terrier P., Vidaud D., Cayre A., et al. Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008 2008, 849156.. 10.1155/2008/849156.
41. Du X., Yang J., Ylipä A., Zhu Z. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. J. Hematol. Oncol. 2013, 6:93. 10.1186/1756-8722-6-93.
42. Mantripragada K.K., Spurlock G., Kluwe L., Chuzhanova N., Ferner R.E., Frayling I.M., et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin. Cancer Res. 2008, 14:1015-1024. 10.1158/1078-0432.CCR-07-1305.
43. Torres K.E., Zhu Q.-S., Bill K., Lopez G., Ghadimi M.P., Xie X., et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin. Cancer Res. 2011, 17:3943-3955. 10.1158/1078-0432.CCR-11-0193.
44. Ohishi J., Aoki M., Nabeshima K., Suzumiya J., Takeuchi T., Ogose A., et al. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β. BMC Cancer 2013, 13:224. 10.1186/1471-2407-13-224.
45. Gudena V., Verma N., Post G., Kizziah M., Fenning R., Montero A.J. Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol. Ther. 2008, 7:810-813. http://www.ncbi.nlm.nih.gov/pubmed/18376142 (accessed 13.10.15).
46. Ambrosini G., Cheema H.S., Seelman S., Teed A., Sambol E.B., Singer S., et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol. Cancer Ther. 2008, 7:890-896. 10.1158/1535-7163.MCT-07-0518.
47. Thomas L.E., Winston J., Rad E., Mort M., Dodd K.M., Tee A.R., et al. Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours. Hum. Genomics 2015, 9:3. 10.1186/s40246-015-0025-3.
48. Teixeira F., Martinez-Palomo A., Riccardi V.M., Fernandez-Diez J. Vascular changes in cutaneous neurofibromas. Neurofibromatosis 1988, 1:5-16. http://www.ncbi.nlm.nih.gov/pubmed/3273410 (accessed 13.10.15).
49. Gesundheit B., Parkin P., Greenberg M., Baruchel S., Senger C., Kapelushnik J., et al. The role of angiogenesis in the transformation of plexiform neurofibroma into malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1. J. Pediatr. Hematol. Oncol. 2010, 32:548-553. 10.1097/MPH.0b013e3181e887c7.
50. Rad E., Dodd K., Thomas L., Upadhyaya M., Tee A. STAT3 and HIF1α signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors. Mol. Cancer Res. 2015, 13:1149-1160. 10.1158/1541-7786.MCR-14-0182.
51. Watson A.L., Rahrmann E.P., Moriarity B.S., Choi K., Conboy C.B., Greeley A.D., et al. Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. Cancer Discov. 2013, 3:674-689. 10.1158/2159-8290.CD-13-0081.
52. Luscan A., Shackleford G., Masliah-Planchon J., Laurendeau I., Ortonne N., Varin J., et al. The activation of the WNT signalling pathway is a hallmark in neurofibromatosis type 1 tumorigenesis. Clin. Cancer Res. 2013, 10.1158/1078-0432.CCR-13-0780.
53. Bradtmöller M., Hartmann C., Zietsch J., Jäschke S., Mautner V.-F., Kurtz A., et al. Impaired Pten expression in human malignant peripheral nerve sheath tumours. PLoS One 2012, 7:e47595. 10.1371/journal.pone.0047595.
54. De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014, 514:247-251. 10.1038/nature13561.
55. Kirmizis A., Bartley S.M., Farnham P.J. Identification of the polycomb group protein SU(Z) 12 as a potential molecular target for human cancer therapy. Mol. Cancer Ther. 2003, 2:113-121. http://www.ncbi.nlm.nih.gov/pubmed/12533679 (accessed 25.09.15).
56. Li H., Cai Q., Wu H., Vathipadiekal V., Dobbin Z.C., Li T., et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol. Cancer Res. 2012, 10:1462-1472. 10.1158/1541-7786.MCR-12-0335.
57. Pasmant E., Masliah-Planchon J., Lévy P., Laurendeau I., Ortonne N., Parfait B., et al. Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Mol. Med. 2016, 17:79-87. 10.2119/molmed.2010.00079.
58. Liu C., Shi X., Wang L., Wu Y., Jin F., Bai C., et al. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumor Biol. 2014, 35:6073-6082. 10.1007/s13277-014-1804-5.
59. Völkel P., Dupret B., Le Bourhis X., Angrand P.-O. Diverse involvement of EZH2 in cancer epigenetics. Am. J. Transl. Res. 2015, 7:175-193. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4399085&tool=pmcentrez&rendertype=abstract (accessed 29.09.15).
60. Sedani A., Cooper D.N., Upadhyaya M. An emerging role for microRNAs in NF1 tumorigenesis. Hum. Genomics 2012, 6:23. 10.1186/1479-7364-6-23.
61. Masliah-Planchon J., Pasmant E., Luscan A., Laurendeau I., Ortonne N., Hivelin M., et al. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics 2013, 14:473. 10.1186/1471-2164-14-473.
62. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2999-3004. 10.1073/pnas.0307323101.
63. Presneau N., Eskandarpour M., Shemais T., Henderson S., Halai D., Tirabosco R., et al. MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. Br. J. Cancer 2013, 108:964--972. 10.1038/bjc.2012.518.
64. Subramanian S., Thayanithy V., West R.B., Lee C.-H., Beck A.H., Zhu S., et al. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J. Pathol. 2010, 220:58-70. 10.1002/path.2633.
65. Gong M., Ma J., Li M., Zhou M., Hock J.M., Yu X. MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. Neuro. Oncol. 2012, 14:1007-1017. 10.1093/neuonc/nos124.